Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)

Inclusion Criteria: * Patients aged 18-80 years * Diagnosis of ischemic heart failure (supported by history of CAD or revascularization by PCI or CABG procedure) without known need for revascularization or feasibility of revascularization * Substantial chronic ischemic myocardial injury as demonstrated by LVEF ≤45% by SPECT and the clinical stage of NYHA II or III * At least 50% viable myocardium (SPECT) * Patency of at least two major coronary arteries and/or bypass grafts supplying their territories (confirmed in angiography within 12 months) * Clinically stable CIHF for at least 3 months on guideline recommended therapy * Signed informed consent Exclusion Criteria: * Other than ischemic cause of cardiomyopathy * Less than 3 months from any substantial therapeutic intervention (such as, e.g. CRT/ICD fitting or revascularization) * Less than 3 months from ACS * BMI lower than 18 or greater than 45kg/m2 * Severe valvular heart disease or left ventricle aneurysm requiring aneurysmectomy or other structural interventions * Candidate for heart transplantation * Active or any history of malignancy or tumor * Moderate or severe immunodeficiency * Chronic immunosuppressive therapy * Acute or chronic infection * Coagulopathies * Known alcohol or drug dependence * Severe renal dysfunction (eGFR\<20mL/min) * Soft tissue disease or local infection in a place of required artery puncture * Pregnancy or breastfeeding * Females of childbearing potential who do not use a highly effective method of contraception * Females of childbearing potential in absence of a negative highly sensitive urine or serum pregnancy test * Participation in any other clinical research study that has not reached the primary efficacy endpoint or otherwise would interfere with the patient's participation in this project * Life expectancy \< 12 months * Any objective or subjective reason for inability to attend follow-up visits * Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the project